Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $2.4 billion.

  • BridgeBio Pharma's Total Non-Current Liabilities rose 55.09% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 55.09%. This contributed to the annual value of $2.4 billion for FY2024, which is 26.20% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Total Non-Current Liabilities is $2.4 billion, which was up 26.20% from $1.9 billion recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Total Non-Current Liabilities registered a high of $2.4 billion during FY2024, and its lowest value of $586.2 million during FY2020.
  • In the last 3 years, BridgeBio Pharma's Total Non-Current Liabilities had a median value of $1.9 billion in 2023 and averaged $2.0 billion.
  • Per our database at Business Quant, BridgeBio Pharma's Total Non-Current Liabilities surged by 285.20% in 2020 and then fell by 0.81% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Total Non-Current Liabilities stood at $586.2 million in 2020, then skyrocketed by 216.68% to $1.9 billion in 2021, then fell by 0.81% to $1.8 billion in 2022, then climbed by 2.28% to $1.9 billion in 2023, then rose by 26.20% to $2.4 billion in 2024.